The primary objective of this study is to evaluate the dose effect of Phenylephrine Hydrochloride Injection on the treatment of clinically relevant decreased blood pressure in the pediatric population, ≥12 to 16 year old patients undergoing general and neuraxial anesthesia. The secondary objectives are to describe changes in blood pressure and heart rate, time to onset and to maximal response, and the duration of response; to assess the safety of the product in this population; and to characterize the pharmacokinetics of phenylephrine hydrochloride.
Full Title of Study: “Phase 4 Open Label Study to Determine Pharmacokinetics of Phenylephrine and Pharmacodynamic Effects on BP Via IV Admin of Phenylephrine Hydrochloride Inj in Ped Subjects (≥12 to 16 Years of Age) Undergoing Gen and Neuraxial Anesthesia”
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: June 2022
This is a Phase 4 multi-center, randomized open-label study in 100 subjects aged ≥12 to 16 years who experience a decrease in blood pressure during a procedure requiring general or neuraxial anesthesia. At least 300 subjects will be enrolled in this study. It is anticipated that up to 33% of enrolled subjects will actually experience a decrease in blood pressure that requires treatment and so will receive Phenylephrine Hydrochloride Injection (PHI). There are 12 possible randomization assignments: one of six initial treatments PHI will be initially administered to approximately 50 subjects as an intravenous bolus (IV-B) at Low (1 μg/kg), Med (3 μg/kg), or High (5 μg/kg) level; PHI will be initially administered to approximately 50 subjects as a continuous intravenous infusion (IV-I) at Low (0.25 μg/kg/min), Med (0.75 μg/kg/min), or High (1.25 μg/kg/min) level]; each initial treatment group will have two pharmacokinetics (PK) sampling schedules.
- Drug: Phenylephrine
- one of six initial treatments Phenylephrine Hydrochloride Injection (PHI) will be initially administered to approximately 50 subjects as an intravenous bolus (IV-B) at Low (1 μg/kg), Med (3 μg/kg), or High (5 μg/kg) level; PHI will be initially administered to approximately 50 subjects as a continuous intravenous infusion (IV-I) at Low (0.25 μg/kg/min), Med (0.75 μg/kg/min), or High (1.25 μg/kg/min) level]; each initial treatment group will have two PK sampling schedules.
Arms, Groups and Cohorts
- Experimental: Phenylephrine
- Phenylephrine Hydrochloride Injection, USP (United States Pharmacopeia) 10 mg/mL label claim
Clinical Trial Outcome Measures
- Plasma Phenylephrine (PE) concentrations will be measured using a validated liquid chromatography/mass spectrometry (LCMS/MS) assay.
- Time Frame: Screening up to Day 3
Participating in This Clinical Trial
1. Subject's age is between ≥12 and 16 years, inclusive 2. Subject is scheduled for a procedure that requires general or neuraxial anesthesia 3. Subjects must have normal or clinically acceptable physical exam 4. Subjects with controlled diabetes prior to entry must have a mean systolic/diastolic office blood pressure ≤128/78 mmHg (sitting, after 5 minutes of rest) 5. Females must have a urine or serum pregnancy test (Human Chorionic Gonadotropin) that is negative at Screening and Day 1 6. Subject's parent or legal guardian gives informed consent and subject gives assent. Exclusion Criteria:
1. Subject has a contraindication to vasoconstrictor therapy for control of blood pressure 2. Subject has participated in other clinical trials for investigational drugs and/or devices within 30 days prior to enrollment 3. Subject has any serious medical condition which, in the opinion of the investigator, is likely to interfere with study procedures 4. Subjects who have a history of any clinically significant local or systemic infectious disease within four weeks prior to initial treatment administration 5. Subjects who are positive for hepatitis B surface antigen or hepatitis C antibody 6. Subjects taking antihypertensive medication 7. Subject is moribund (death is likely to occur in less than 48 hours) 8. Females who are pregnant, nursing or unwilling to use/practice adequate contraception.
Gender Eligibility: All
Minimum Age: 12 Years
Maximum Age: 16 Years
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
- Lead Sponsor
- West-Ward Pharmaceutical
- Provider of Information About this Clinical Study
- Overall Official(s)
- Cesar Ormeno, MD, Study Director, PRA Health Sciences
- Overall Contact(s)
- J. Barton Kalis, 856-489-2247, email@example.com
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.